Appropriate use of laser photocoagulation and anti-vascular endothelial growth factor drugs, to treat the diabetic retinopathy effectively
10.3760/cma.j.cn511434-20201013-00490
- VernacularTitle:合理使用激光与抗血管内皮生长因子药物，提高糖尿病视网膜病变的治疗水平
- Author:
Xiaoling LIU
1
;
Zuhua SUN
Author Information
1. 温州医科大学附属眼视光医院 325027
- From:
Chinese Journal of Ocular Fundus Diseases
2020;36(10):749-753
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic retinopathy (DR) is a major and irreversible blinding eye disease in working aged adults. Diabetic macular edema (DME) is a complication of the further development of DR, and it is one of the main causes of vision loss in DR patients. The emergence of anti-VEGF drugs has changed the treatment model of DR and DME. Firstly, for the treatment of DME, the previous focal/grid-like laser photocoagulation is converted to anti-VEGF drugs as the first-line treatment. Secondly, for the treatment of proliferative DR (PDR), panretinal photocoagulation (PRP) was the gold standard in the past, and now anti-VEGF drugs have become an alternative treatment for some PDR patients. In varying degrees of DR and DME, the option of treatment, anti-VEGF drug therapy replacing PRP, and the era of anti-VEGF drug therapy on DR treatment modes are worthy questions for consideration by clinicians. In-depth study of the clinical study of PRP and anti-VEGF drugs in the treatment of DR, the changes attention in clinical guidelines and expert consensus, the gradual establishment of treatment of DR and DME suitable, and the personalized treatment of DR patients may help improve the level of DR treatment in China.
